Key Takeaways
- • Schrödinger co-founded Tectora Therapeutics with New Enterprise Associates (NEA) and RA Capital Management, a specialized biotech vehicle focused on immunology and inflammation drug development, closing a $55 million Series A funding round.
- • Schrödinger contributed two early-stage small molecule programs (SDGR-4594 and SDGR-8139) to Tectora in exchange for an equity stake plus eligibility for future milestone payments and royalties, maintaining ongoing collaboration through its computational drug discovery platform.
- • The transaction exemplifies Schrödinger's established strategy of creating and licensing programs to external partners; the company reports that prior partnerships (Nimbus, Morphic, Structure, Ajax) have collectively generated over $750 million in proceeds.
- • Tectora will leverage Schrödinger's computational platform and drug discovery expertise to advance its immunology programs toward clinical candidates, combining early-stage science with dedicated venture capital and sector expertise.
- • The formation underscores continued investor confidence in AI-enabled drug discovery models and targeted therapeutic development within specialized disease areas, with NEA and RA Capital both recognized as science-focused multi-stage life sciences investors.
Summary
Schrödinger, Inc. (Nasdaq: SDGR) announced on September 10, 2026, the formation of Tectora Therapeutics, a newly co-founded biotechnology company developed in partnership with New Enterprise Associates (NEA) and RA Capital Management. Tectora closed a $55 million Series A funding round led by both NEA and RA Capital, positioning the company to advance innovative immunology and inflammation therapies.
As part of the transaction structure, Schrödinger contributed two early-stage small molecule drug candidates (SDGR-4594 and SDGR-8139) to Tectora's pipeline. In exchange, Schrödinger retained an equity stake in the newly formed company and secured eligibility for future milestone payments and royalties tied to the programs' clinical and commercial progress. Critically, Tectora will continue to partner with Schrödinger's drug discovery team and retain access to Schrödinger's computational chemistry platform to advance these candidates toward clinical development stages.
Karen Akinsanya, Ph.D., President of Therapeutics R&D and Chief Strategy Officer, Partnerships, at Schrödinger, emphasized the company's track record in this model: "We co-founded Tectora with NEA and RA Capital to pair our breakthrough science with the dedicated capital and industry expertise needed to rapidly advance these programs to patients." Akinsanya noted that Schrödinger's prior partnerships—including Nimbus, Morphic, Structure Therapeutics, and Ajax Pharmaceuticals—have collectively generated over $750 million in proceeds, demonstrating the financial viability of the licensing and co-founding strategy.
The collaboration aligns with Schrödinger's broader revenue growth trajectory, which has increasingly shifted toward drug discovery collaborations and licensing arrangements since 2020. The company maintains operational partnerships across more than 25 drug discovery programs, leveraging its proprietary computational platform as a competitive moat. J.C. Lopez, Principal at New Enterprise Associates, characterized the investment thesis as seeking "opportunities where exceptional science is paired with a motivated entrepreneurial team," reflecting investor appetite for science-driven biotech vehicles with focused therapeutic mandates.
As part of the transaction structure, Schrödinger contributed two early-stage small molecule drug candidates (SDGR-4594 and SDGR-8139) to Tectora's pipeline. In exchange, Schrödinger retained an equity stake in the newly formed company and secured eligibility for future milestone payments and royalties tied to the programs' clinical and commercial progress. Critically, Tectora will continue to partner with Schrödinger's drug discovery team and retain access to Schrödinger's computational chemistry platform to advance these candidates toward clinical development stages.
Karen Akinsanya, Ph.D., President of Therapeutics R&D and Chief Strategy Officer, Partnerships, at Schrödinger, emphasized the company's track record in this model: "We co-founded Tectora with NEA and RA Capital to pair our breakthrough science with the dedicated capital and industry expertise needed to rapidly advance these programs to patients." Akinsanya noted that Schrödinger's prior partnerships—including Nimbus, Morphic, Structure Therapeutics, and Ajax Pharmaceuticals—have collectively generated over $750 million in proceeds, demonstrating the financial viability of the licensing and co-founding strategy.
The collaboration aligns with Schrödinger's broader revenue growth trajectory, which has increasingly shifted toward drug discovery collaborations and licensing arrangements since 2020. The company maintains operational partnerships across more than 25 drug discovery programs, leveraging its proprietary computational platform as a competitive moat. J.C. Lopez, Principal at New Enterprise Associates, characterized the investment thesis as seeking "opportunities where exceptional science is paired with a motivated entrepreneurial team," reflecting investor appetite for science-driven biotech vehicles with focused therapeutic mandates.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.